Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -5.88% is 73% above its 5-year average of -21.39%, near the high end of its 5-year range (-38.88%–-5.88%).
44.89% above its 12-month average of -10.67%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -1.64%.
RETURN ON ASSETS (ROA)
-5.88%
RETURN ON ASSETS (ROA) AVG TTM
-10.67%
RETURN ON ASSETS (ROA) AVG 3Y
-19.76%
RETURN ON ASSETS (ROA) AVG 5Y
-21.39%
RETURN ON ASSETS (ROA) AVG 10Y
-33.48%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+44.89%
CURRENT VS 3Y AVG
+70.24%
CURRENT VS 5Y AVG
+72.50%
CURRENT VS 10Y AVG
+82.44%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+81.76%
vs the sector median at left
SI-BONE, Inc.
Market Cap
$867.03M
Return on Assets (ROA)
-5.88%
TTM Avg
-10.67%
3Y Avg
-19.76%
5Y Avg
-21.39%
Market Cap
$870.81M
Return on Assets (ROA)
-55.10%
TTM Avg
-55.10%
3Y Avg
-55.10%
5Y Avg
-55.10%
Market Cap
$857.16M
Return on Assets (ROA)
-18.34%
TTM Avg
-25.78%
3Y Avg
-11.37%
5Y Avg
4.46%
Market Cap
$855.38M
Return on Assets (ROA)
-78.30%
TTM Avg
-72.68%
3Y Avg
-105.45%
5Y Avg
-105.45%
Market Cap
$853.13M
Return on Assets (ROA)
61.78%
TTM Avg
41.06%
3Y Avg
4.27%
5Y Avg
-3.43%
Market Cap
$852.35M
Return on Assets (ROA)
-135.59%
TTM Avg
-77.84%
3Y Avg
-48.75%
5Y Avg
-48.75%
Market Cap
$884.97M
Return on Assets (ROA)
55.85%
TTM Avg
-44.25%
3Y Avg
-43.62%
5Y Avg
-43.05%
Market Cap
$887.50M
Return on Assets (ROA)
8.09%
TTM Avg
-0.64%
3Y Avg
-8.03%
5Y Avg
-4.54%
Market Cap
$887.99M
Return on Assets (ROA)
-22.62%
TTM Avg
-55.95%
3Y Avg
-57.94%
5Y Avg
-46.38%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| SI-BONE, Inc. (SIBN) | $867.03M | -5.88% | -10.67% | -19.76% | -21.39% |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $870.81M | -55.10% | -55.10% | -55.10% | -55.10% |
| QuidelOrtho Corporation (QDEL)vs › | $857.16M | -18.34% | -25.78% | -11.37% | 4.46% |
| Alumis Inc. (ALMS)vs › | $855.38M | -78.30% | -72.68% | -105.45% | -105.45% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $853.13M | 61.78% | 41.06% | 4.27% | -3.43% |
| SL Science Holding Ltd (SLBT)vs › | $852.35M | -135.59% | -77.84% | -48.75% | -48.75% |
| Arbutus Biopharma Corp (ABUS)vs › | $884.97M | 55.85% | -44.25% | -43.62% | -43.05% |
| Bioventus Inc. (BVS)vs › | $887.50M | 8.09% | -0.64% | -8.03% | -4.54% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $887.99M | -22.62% | -55.95% | -57.94% | -46.38% |
| Pacific Biosciences of California, Inc. (PACB)vs › | $838.62M | -17.48% | -47.13% | -32.40% | -21.92% |
ROA
-5.9%
ROE
-8.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -7.93% |
| 2024-12-31 | -13.41% |
| 2023-12-31 | -18.81% |
| 2022-12-31 | -38.88% |
| 2021-12-31 | -29.70% |
| 2020-12-31 | -19.58% |
| 2019-12-31 | -32.82% |
| 2018-12-31 | -12.60% |
| 2017-12-31 | -64.29% |
| 2016-12-31 | -52.21% |
| 2015-12-31 | -78.09% |
| 2014-12-31 | -95.93% |
| 2013-12-31 | -34.16% |
| 2012-12-31 | 0.00% |
